Press release
Duchenne Muscular Dystrophy Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers
Explore our latest breakthroughs in Duchenne Muscular Dystrophy Research. Learn more about our innovative pipeline today! @ Duchenne Muscular Dystrophy Pipeline Outlook [https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Duchenne Muscular Dystrophy Pipeline Report
* In October 2024:- Hoffmann-La Roche- The purpose of this study is to assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of satralizumab, a humanized anti-interleukin-6 receptor (aIL-6R) monoclonal antibody, in ambulatory and non-ambulatory patients with Duchenne muscular dystrophy (DMD) age greater than or equal to 8 to < 16 years old receiving corticosteroid therapy.
* In October 2024:- Sarepta Therapeutics Inc.- This study will be comprised of 2 parts: 1) Part A (Multiple Ascending Dose [MAD]) will be conducted to evaluate the safety and tolerability of vesleteplirsen at MAD levels to determine the maximum tolerated dose (MTD), and 2) Part B will be conducted to further evaluate the vesleteplirsen doses selected in Part A. Participants enrolling in Part B will be those who completed Part A or Study 5051-102 (NCT03675126) and meet applicable eligibility criteria for Part B, as well as additional participants who meet applicable eligibility criteria for enrollment at the beginning of Part B.
* DelveInsight's Duchenne Muscular Dystrophy pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Duchenne Muscular Dystrophy treatment.
* The leading Duchenne Muscular Dystrophy Companies such as Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, EDG 5506 Edgewise Therapeutics, Fordadistrogene movaparvovec, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma , and others.
* Promising Duchenne Muscular Dystrophy Therapies such as Vamorolone, Sevasemten 10 mg, Givinostat, DS-5141b, SGT-003, PF-06939926, NS-089/NCNP-02 , and others.
Stay informed about the cutting-edge advancements in Duchenne Muscular Dystrophy Treatments. Download for updates and be a part of the revolution in Musculoskeletal Care @ Duchenne Muscular Dystrophy Clinical Trials Assessment [https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Duchenne Muscular Dystrophy Emerging Drugs
* Vamorolone: Santhera
Vamorolone is a first-in-class drug candidate that binds to the same receptors as corticosteroids but modifies the downstream activity of the receptors1,2. This has the potential to 'dissociate' efficacy from typical steroid safety concerns and therefore could emerge as a valuable alternative to corticosteroids, the current standard of care in children and adolescent patients with DMD. There is a clear unmet medical need in this patient group as high dose corticosteroids have significant systemic side effects that detract from patient quality of life. On September 2, 2020, Santhera exercised its option and obtained worldwide rights to vamorolone in Duchenne muscular dystrophy and all other indications. Santhera and ReveraGen expect to complete the rolling NDA submission to the U.S. FDA in June 2022.
* Givinostat: Italfarmaco
Givinostat, is an HDAC inhibitor (HDACi, a principle candidate, currently being developed for the treatment of DMD and BMD. Since Givinostat acts on the pathogenetic events downstream of the genetic defects, it is potentially a treatment for the whole DMD and BMD population and to counter the disease pathogenetic events in all muscular districts.
* Pamrevlumab: Fibrogen
Pamrevlumab is a first-in-class antibody developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF), a common factor in fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure. Pamrevlumab is advancing towards Phase 3 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF) and pancreatic cancer and has been granted Orphan Drug Designation (ODD) in each of these indications, and is currently in a Phase 2 trial for Duchenne muscular dystrophy (DMD).
Learn more about Duchenne Muscular Dystrophy Drugs opportunities in our groundbreaking Duchenne Muscular Dystrophy Research and development projects @ Duchenne Muscular Dystrophy Unmet Needs [https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Duchenne Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
* Oral
* Intravenous
* Subcutaneous
Duchenne Muscular Dystrophy Products have been categorized under various Molecule types such as
* Small molecule
* Cell Therapy
* Peptides
* Polymer
* Small molecule
* Gene therapy
Discover the latest advancements in Duchenne Muscular Dystrophy Treatment by visiting our website. Stay informed about how we're transforming the future of musculoskeletal @ Duchenne Muscular Dystrophy Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Duchenne Muscular Dystrophy Pipeline Report
* Coverage- Global
* Duchenne Muscular Dystrophy Companies- Santhera Pharmaceuticals, Sarepta Therapeutics, Italfarmaco, Wave Life Sciences Ltd, FibroGen, EDG 5506 Edgewise Therapeutics, Fordadistrogene movaparvovec, Daiichi Sankyo, Sarepta Therapeutics, Inc., ENCell, Taiho Pharmaceutical, Solid Biosciences, Capricor, Nippon Shinyaku, Hansa Biopharma, and others.
* Duchenne Muscular Dystrophy Therapies- Vamorolone, Sevasemten 10 mg, Givinostat, DS-5141b, SGT-003, PF-06939926, NS-089/NCNP-02, and others.
* Duchenne Muscular Dystrophy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Duchenne Muscular Dystrophy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Duchenne Muscular Dystrophy Pipeline on our website @ Duchenne Muscular Dystrophy Drugs and Companies [https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Duchenne Muscular Dystrophy: Overview
* Pipeline Therapeutics
* Therapeutic Assessment
* Duchenne Muscular Dystrophy- DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Delandistrogene moxeparvovec: Roche
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* SRP 5051: Sarepta Therapeutics
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I/II)
* WVE N531: Wave Life Sciences
* Drug profiles in the detailed report.....
* Early Stage Products (Phase I)
* EDG 5506: Edgewise Therapeutics
* Drug profiles in the detailed report.....
* Inactive Products
* Duchenne Muscular Dystrophy Key Companies
* Duchenne Muscular Dystrophy Key Products
* Duchenne Muscular Dystrophy- Unmet Needs
* Duchenne Muscular Dystrophy- Market Drivers and Barriers
* Duchenne Muscular Dystrophy- Future Perspectives and Conclusion
* Duchenne Muscular Dystrophy Analyst Views
* Duchenne Muscular Dystrophy Key Companies
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=duchenne-muscular-dystrophy-pipeline-therapeutics-assessment-companies-products-unmet-needs-market-drivers-and-barriers]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Duchenne Muscular Dystrophy Pipeline Therapeutics, Assessment, Companies, Products, Unmet Needs, Market Drivers and Barriers here
News-ID: 3694540 • Views: …
More Releases from ABNewswire
Boca Raton Moving Broker Sees Surge in Demand as Families Seek Transparent Inter …
Safe Ship Moving Services, a Boca Raton-based interstate moving broker, reports rising demand as families, businesses, and military households seek transparent pricing and reliable communication. By matching customers with vetted, licensed carriers nationwide, the company has coordinated over 40,000 moves while emphasizing upfront estimates, virtual consultations, and strict carrier screening standards.
Safe Ship Moving Services has coordinated more than 40,000 household relocations across state lines since launching operations from its Boca…
How to Create a CapCut Template in 2026: A Complete Creator's Playbook
Image: https://www.abnewswire.com/upload/2026/02/4e061e81741ac5e16f33937c9ebbf9c8.jpg
Designing your own CapCut templates is no longer just a "nice-to-have" skill. In 2026, templates are one of the fastest ways to edit consistently, protect your visual identity, and scale content production without burning out.
This in-depth guide walks you through how to build CapCut templates from the ground up, whether you are editing on mobile or desktop. You will also learn how to structure reusable workflows, avoid common mistakes,…
Marketing Strategist Katina Ndlovu Demonstrates How Google Local Services Ads Ca …
This case study examines how a service-based business generated 280 high-intent leads in two months using Google Local Services Ads by focusing on phone-driven enquiries, trust signals, and operational readiness rather than traffic volume. The campaign achieved consistent top-of-search visibility, capturing decision-ready customers and producing stable inbound demand. It highlights why aligning marketing systems with real buyer behaviour is essential for sustainable local growth.
Johannesburg, South Africa - Marketing strategy consultant…
How to Build a Red Light + Skincare Regimen for Visible Results All Year
Mito Red Light is pioneering a new category of skincare known as Light-Activated Skincare, combining red and near-infrared light therapy with topical formulations designed to respond to light exposure. The company's latest educational release outlines how to build a year-round red light skincare regimen using its MitoAURA Trademark Activate + Amplify Serum, while announcing an upcoming split-face study to evaluate the added benefits of light-activated skincare compared to light therapy…
More Releases for Duchenne
Duchenne Muscular Dystrophy (DMD) Market Growth in 2034
Market Overview
The Duchenne Muscular Dystrophy (DMD) Market is expanding rapidly as advances in genetic medicine, exon-skipping therapies, gene therapy platforms, and improved diagnostic capabilities reshape treatment options for this severe, progressive neuromuscular disorder.
DMD is caused by mutations in the dystrophin gene, leading to muscle degeneration beginning in early childhood. Growing awareness among clinicians and caregivers, widespread adoption of next-generation sequencing (NGS), and increasing availability of disease-modifying therapies have significantly strengthened…
Duchenne Muscular Dystrophy: Core Growth Enabler in the Rising Prevalence Of Chr …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
What Will the Duchenne Muscular Dystrophy Industry Market Size Be by 2025?
The market size for Duchenne Muscular Dystrophy has shown significant expansion recently, burgeoning from $1.16 billion in 2024 to $1.25 billion in 2025 at a compound annual growth rate (CAGR) of 7.9%. The impressive growth in the…
Shaping the Duchenne Muscular Dystrophy (DMD) Therapeutics Market in 2025: Bit B …
How Big Is the Duchenne Muscular Dystrophy (DMD) Therapeutics Market Expected to Be, and What Will Its Growth Rate Be?
The Duchenne muscular dystrophy (DMD) therapeutics market will grow from $11.95 billion in 2024 to $16.45 billion in 2025, at a CAGR of 37.6%. The growth is attributed to the increasing prevalence of Duchenne muscular dystrophy, rising awareness of treatment options, healthcare spending, and government initiatives.
The Duchenne muscular dystrophy (DMD) therapeutics…
Duchenne Muscular Dystrophy Pipeline Outlook Report 2024
DelveInsight's, "Duchenne Muscular Dystrophy Pipeline Insight 2024" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Duchenne Muscular Dystrophy pipeline landscape. It covers the Duchenne Muscular Dystrophy pipeline drug profiles, including Duchenne Muscular Dystrophy clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
…
Duchenne Muscular Dystrophy Treatmcent Market
Global Duchenne Muscular Dystrophy Treatmcent Market Set for Robust Growth During Forecast Period
The global Duchenne Muscular Dystrophy Treatment Market is poised to witness significant growth at a high Compound Annual Growth Rate (CAGR) during the forecast period of 2023 to 2030. Duchenne muscular dystrophy (DMD) stands as a genetic disorder marked by progressive muscle degeneration and weakness, with therapeutics aimed at addressing the absence of dystrophin, a crucial protein in…
Duchenne Muscular Dystrophy (DMD) Drugs Market Report
As per the research conducted by GME, the Duchenne Muscular Dystrophy (DMD) Drugs Market will grow with a CAGR value of 41.3 percent by 2026. The global market for Duchenne muscular dystrophy is foreseen to grow due to accelerated research and development activities, expanded patient awareness for effective treatments, and the launch of new medications Moreover, the disease's increasing prominence is likely to drive the global duchenne muscular dystrophy market…
